[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
December 1, 2010

Active Surveillance for Prostate Cancer

Author Affiliations

Author Affiliations: Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio (Dr Thompson); and Sunnybrook Health Science Centre, Toronto, Ontario, Canada (Dr Klotz).

JAMA. 2010;304(21):2411-2412. doi:10.1001/jama.2010.1761

Since 1980, the prognosis of prostate cancer has changed markedly as the United States has moved through 3 eras. The first era reflected the experience of the prior century. Because prostate cancer is usually asymptomatic until it is metastatic and rectal examination has a low sensitivity for early cancer detection, most men had advanced and incurable disease at diagnosis. During the second era in the mid-1980s, with the advent of prostate-specific antigen (PSA) testing, at-risk men underwent prostate biopsy, leading to a doubling of incidence rates and a stage shift, with a substantially higher fraction of men with curable disease at diagnosis.1 This increase in numbers of patients suitable for curative therapy (surgery or radiation) facilitated a reduction in complications and morbidity. The increasing proportion of men achieving long-term cure was gratifying. Even though randomized studies of screening have reached discordant conclusions about how screening affects cure, prostate cancer mortality declined 39% in the United States from 1990 to 2006.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×